Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on January 20 at 3:00 p.m. ET. The presentation will be accessible via a live audio webcast on Geron's website, with a replay available for 30 days post-event.
Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor targeting hematologic myeloid malignancies. For further details, visit www.geron.com.
- None.
- None.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.
A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. A replay of the webcast will be available on the Company’s website for 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005809/en/
FAQ
When will Geron Corporation present at the B. Riley Securities Virtual Oncology Investor Conference?
How can I access Geron's presentation at the investor conference?
What is the focus of Geron Corporation's development efforts?
Will there be a replay of Geron's presentation available?
What is the stock symbol for Geron Corporation?
